---
title: "Scinai Immunotherapeutics soars 41% during regular trading to $2.34"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/298944640.md"
description: "SCNI shares climbed 41% intraday, hitting $2.67 high and leading medical sector gains."
datetime: "2026-09-14T16:22:38.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/298944640.md)
  - [en](https://longbridge.com/en/news/298944640.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/298944640.md)
generator: "portal-rs"
---

# Scinai Immunotherapeutics soars 41% during regular trading to $2.34

Scinai Immunotherapeutics(SCNI.US) 盘中涨**40.96%**，现报**2.34**美元。

该股盘中 5 分钟内触发急涨信号，一度触及盘中高位**2.67**美元。消息显示，该股盘前已大涨约 40%，随后在正常交易中继续走高，领涨医疗板块个股。

### Related Stocks

- [SCNI.US](https://longbridge.com/en/quote/SCNI.US.md)

## Related News & Research

- [Scinai ends PC111 licensing deal, shifts R&D focus to NanoAb platform](https://longbridge.com/en/news/298326828.md)
- [Scinai Immunotherapeutics: Expanded CDMO platform drives growth, but operating losses persist as revenue scales](https://longbridge.com/en/news/297069758.md)
- [‘Open Your Eyes,’ Says Top Investor About Oracle Stock](https://longbridge.com/en/news/301160283.md)
- [Marvell Now Sees as Much as $90 Billion in Annual Sales by Fiscal 2031. Here's Why It's a Chip Stock to Buy.](https://longbridge.com/en/news/301114413.md)
- [Palantir vs. Oracle – Why Daniel Ives Says Buy One, Hold the Other](https://longbridge.com/en/news/301155464.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**